Free Trial

Sera Prognostics Q3 2024 Earnings Report

Sera Prognostics logo
$3.54 -0.36 (-9.23%)
As of 03/28/2025 04:00 PM Eastern

Sera Prognostics EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.22
Beat/Miss
Missed by -$0.02
One Year Ago EPS
-$0.23

Sera Prognostics Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.09 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Sera Prognostics Earnings Headlines

Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
TD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA), a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

View Sera Prognostics Profile

More Earnings Resources from MarketBeat